Disclosures for "Design of ADAPT FORWARD, a Phase 2a Study to Evaluate the Safety, Efficacy, and Tolerability of Intravenous Empasiprubart as an Add-on Therapy to Intravenous Efgartigimod in Adult Participants with Generalized Myasthenia Gravis"
-
Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has or had stock in argenx.
-
Dr. Bilgraer has nothing to disclose.
-
Dr. Dosne has nothing to disclose.
-
Sophie Steeland has received personal compensation for serving as an employee of argenx. Sophie Steeland has stock in argenx.
-
Ms. Heerlein has received personal compensation for serving as an employee of argenx. Ms. Heerlein has received personal compensation for serving as an employee of JNJ. Ms. Heerlein has or had stock in argenx.Ms. Heerlein has or had stock in JNJ.
-
Dr. Vangeneugden has received personal compensation for serving as an employee of Argenx. Dr. Vangeneugden has stock in Argenx.
-
Mrs. Ramos-Masa has received personal compensation for serving as an employee of argenx. Mrs. Ramos-Masa has stock in argenx.